Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ferric derisomaltose - Pharmacosmos

Drug Profile

Ferric derisomaltose - Pharmacosmos

Alternative Names: Diafer; Iron isomaltoside 1000; Iron oligosaccharide; Isofer; Jilazo; Monofar; Monofer; MONOFERRIC; Monoferric; Monover; NS 32

Latest Information Update: 20 Jan 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pharmacosmos
  • Developer Cosmopharm; Nippon Shinyaku; Pfizer; Pharmacosmos
  • Class Antianaemics; Disaccharides; Ferric compounds
  • Mechanism of Action Iron replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Iron deficiency anaemia
  • Phase III Metabolic disorders

Most Recent Events

  • 20 Jan 2020 Launched for Iron deficiency anaemia in Canada (IV, Injection and Infusion) prior to January 2020
  • 16 Jan 2020 Registered for Iron deficiency anaemia in USA (IV, Injection and Infusion)
  • 12 Aug 2019 Phase-III clinical trials in Iron deficiency anaemia in Japan before August 2019 (IV, Injection) (JapicCTI-194888) (Nippon Shinyaku pipeline August 2019)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top